Cytochrome P450 2D6 Antibody (YA3384)
(Synonyms: CYP2D6; CYP2DL1; Cytochrome P450 2D6; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase)Based on 1 Customer Validation
Cytochrome P450 2D6 Antibody (YA3384) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytochrome P450 2D6.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, FC
-
Reactivity :
Human
-
Formulation:
Supplied in rabbit IgG in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
FC
FC: Flow Cytometry
|
|---|---|---|---|---|
| Dilution Ratio | 1:1000-1:2000 | 1:100-1:200 | 1:50-1:200 | 1:50-1:100 |
Product Details
Cytochrome P450 2D6 Antibody (YA3384) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytochrome P450 2D6.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman
-
Observed Molecular WeightObserved band size: 56 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 56 kDa
A synthesized peptide derived from human Cytochrome P450 2D6 aa300-497/497.
Endogenous
Affinity Chromatography
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in rabbit IgG in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% sodium azide and 0.05% BSA.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Verification Images
-
Immunohistochemical analysis of paraffin-embedded human liver using Cytochrome P450 2D6 antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P83639, 1/200) for 1 hour at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human liver cancer using Cytochrome P450 2D6 antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P83639, 1/200) for 1 hour at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
Background
-
Function
Cytochrome P450 2D6 is an A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling. Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis. Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid. Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants[1][2][3][4][5][6].
-
Subcellular Localization
Endoplasmic reticulum membrane; Peripheral membrane protein; Microsome membrane; Peripheral membrane protein
-
Expression
Induction:By pregnancy -
Isoforms & Post-Translational Modification
P10635 has 2 isomers: P10635-1: 55769 Da (predicted); P10635-2: 50061 Da (predicted).
-
SwissProt ID
-
Synonyms
CYP2D6; CYP2DL1; Cytochrome P450 2D6; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase
-
Research Field
Cardiovascular
Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
User Guide for Antibodies (1077 KB)
References
[1]. Snider NT, et al. The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6. J Pharmacol Exp Ther. 2008 Nov;327(2):538-45. [Content Brief]
[2]. Lucas D, et al. Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450. J Lipid Res. 2010 May;51(5):1125-33. [Content Brief]
[3]. Mesaros C, et al. Analysis of epoxyeicosatrienoic acids by chiral liquid chromatography/electron capture atmospheric pressure chemical ionization mass spectrometry using [13C]-analog internal standards. Rapid Commun Mass Spectrom. 2010 Nov 30;24(22):3237-47. [Content Brief]
[4]. Sridar C, et al. Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6. Drug Metab Dispos. 2011 May;39(5):782-8. [Content Brief]
[5]. Honda A, et al. Cholesterol 25-hydroxylation activity of CYP3A. J Lipid Res. 2011 Aug;52(8):1509-16. [Content Brief]
[6]. Chen H, et al. Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos. 2000 Mar;28(3):315-22. [Content Brief]